台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

PD5-2: Comparison of stone-free rate between percutaneous nephrolithotomy and retrograde intrarenal surgery

2019-06-27 • 觀看: 1519 • 回應: 0 • doc
PD5-1: Using the novel “structural equation modeling” to analyze factors and pathways on the development of uric acid nephrolithiasis

2019-06-27 • 觀看: 1398 • 回應: 0 • doc
PD4-6: Biopsy grade group 1: underestimation and outcomes after RaLRP

2019-06-27 • 觀看: 1458 • 回應: 0 • doc
PD4-5: Pathological staging prediction rate of mpMRI in prostate cancer- CMUH experience

2019-06-27 • 觀看: 1442 • 回應: 0 • doc
PD4-4: Heteronemin exhibited cytotoxic effects in prostate cancer cells via oxidative and ER stress involved by protein tyrosine phosphatases activation

2019-06-27 • 觀看: 1473 • 回應: 0 • doc
PD4-3: Analysis of biochemical recurrence among pathology T2+ patients with prostate cancer

2019-06-27 • 觀看: 1414 • 回應: 0 • doc
PD4-2: Tumor-originated exosomal prothymosin-α triggers muscle wasting in bladder cancers

2019-06-27 • 觀看: 1397 • 回應: 0 • doc
PD4-1: Identification, propagation and characterisation of circulating renal cancer stem cells

2019-06-27 • 觀看: 1400 • 回應: 0 • doc
PD3-6: The role of RENAL, PADUA, C-index, CSA nephrometry systems in predicting individual renal function after partial nephrectomy

2019-06-27 • 觀看: 1661 • 回應: 0 • doc
PD3-5: Prognostic value of USP2 overexpression in upper tract urothelial carcinomas in Taiwan.

2019-06-27 • 觀看: 1512 • 回應: 0 • doc
PD3-4: Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan, direct comparison from Taiwan-Japan UTUC collaboration cohort.

2019-06-27 • 觀看: 1625 • 回應: 0 • doc
PD3-3: Miconazole, an anti-fungal agent, exerts bladder cancer chemoprevention by NRF2 activation

2019-06-27 • 觀看: 1439 • 回應: 0 • doc

Prev
741
742
743
744
745
746
747
748
749
750
Next
/ 1052